Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease
The Oncologist · 08.05.2025 · 30 (5)
DOI: 10.1093/oncolo/oyaf063 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 27.05.2025. Verfasst von Sheng Zhang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Paget Disease, Extramammary, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Objective Metastatic Extramammary Paget’s disease (EMPD) is an extremely rare cancer and has a dismal prognosis. The rarity of metastatic EMPD has made the clinical trial almost unfeasible, thus high-quality retrospective analysis is valuable. Methods The electronic medical files of patients with metastatic EMPD treated from Jan 2017 to April 2024 in a tertiary cancer center in China were reviewed, and available tissues were collected for HER2 staining, if possible. Eleven patients were treated with the anti-HER2 antibody-drug conjugate Disitamab vedotin (DV), using doses of 2 mg/kg, once every 3 to 4 weeks. The efficacy and toxicity data were extracted. Key Findings and Limitations: Treatment with the antibody-drug conjugate DV elicited an objective response in 8 of 11 patients (73%), and CEA response in 10 of the 11 patients (91%). The median progression-free interval was 5.5 months. The median overall survival was 21.9 months. This efficacy was accompanied by mild grade 1 or 2 treatment-related toxicity and no grade 3 toxicity. This study is limited by a small sample size, retrospective nature, and inevitable selection bias. Conclusions and Clinical Implications Antibody-drug conjugate targeting of HER2 might be an active treatment for metastatic EMPD. We have initiated a clinical trial to confirm it prospectively. Implication for practice Metastatic Extramammary Paget’s disease (EMPD) is an extremely rare cancer without standard treatment. Treatment with the antibody-drug conjugate DV (an anti-HER2 antibody-drug conjugate) elicited an objective response in 8 of the 11 patients (73%), and CEA response in 10 of the 11 patients (91%). This efficacy was accompanied by mild treatment-related toxicity. Antibody-drug conjugate targeting of HER2 might be an active treatment for metastatic EMPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.
- Pathology, Shanghai Cancer Center, Fudan University, Shanghai, China.
- Breast surgery, the affiliated hospital of Qingdao Universisty, Qingdao, China.
- Department of Biochemistry and Molecular Biology, College of Basic Medical Sciences, Naval Medical University, Shanghai, China.
- Medical oncology, RenJi Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China.
- Musculoskeletal Oncology, Shanghai Cancer Center, Fudan University, Shanghai, China.
ORCID-Profile: Sheng Zhang
Zitieren
APA
Zhang, S., Zhou, J., Zhao, X., Gan, H., Peng, W., Li, W., Sun, M., Hu, J., & Yan, W. (2025). Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease. The Oncologist, 30(5). https://doi.org/10.1093/oncolo/oyaf063
Vancouver
Zhang S, Zhou J, Zhao X, Gan H, Peng W, Li W, et al. Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease. The Oncologist. 2025;30(5). doi:10.1093/oncolo/oyaf063
BibTeX
@article{Zhang2025,
author = {Zhang, Sheng and Zhou, Juan and Zhao, Xiaoying and Gan, Hualei and Peng, Wenxia and Li, Wenfeng and Sun, Mingjuan and Hu, Jiong and Yan, Wangjun},
title = {Antibody-drug conjugate (disitamab vedotin) therapy targeting HER2-low or higher advanced extramammary Paget’s disease},
journal = {The Oncologist},
year = {2025},
volume = {30},
number = {5},
doi = {10.1093/oncolo/oyaf063}
}
EUVIMED